Captisol-enabled busulfan - Ligand Pharmaceuticals

Drug Profile

Captisol-enabled busulfan - Ligand Pharmaceuticals

Alternative Names: CE-Busulfan

Latest Information Update: 19 Oct 2015

Price : $50

At a glance

  • Originator Ligand Pharmaceuticals
  • Developer Ligand Pharmaceuticals; University of Kansas
  • Class Antineoplastics; Butylene glycols; Glycols; Mesylates; Myeloablative agonists; Small molecules
  • Mechanism of Action Alkylating agents; DNA cross linking agents; DNA synthesis inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Haematological malignancies

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 01 Sep 2015 Captisol-enabled busulfan is available for licensing as of 01 Sep 2015. http://www.ligand.com/
  • 01 Sep 2015 Preclinical trials in Haematological malignancies in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top